SHELSEA MCCARTHY: Open Payments
NPI 1629531959 · CHARLOTTE HALL, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$748 in 37 payments from 16 companies in 2025. Trend: 2023 $279 · 2024 $402 · 2025 $748
Food & beverage: $748
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $241 |
| PFIZER INC. | 4 | $92 |
| Insmed, Inc. | 3 | $61 |
| AstraZeneca Pharmaceuticals LP | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $55 |
| Lilly USA, LLC | 2 | $40 |
| Novo Nordisk Inc | 2 | $39 |
| Abbott Laboratories | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
Products named: UBRELVY, QULIPTA, Arikayce, VRAYLAR, TRELEGY ELLIPTA, PREVNAR 20, AIRSUPRA, RINVOQ.
Industry payments across MD — which companies pay providers there.
